Inventor
WEIMER THOMAS
DE29 patents
⚠️ This page may combine multiple inventors who share the name “WEIMER THOMAS”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
CSL Behring Lengnau AG
8 patentsUS10688157B2Jun 23, 2020
Truncated von Willebrand factor polypeptides for treating hemophilia
CSL Behring Lengnau AG2 citations72
US10905747B2Feb 2, 2021
Methods for preparing modified von Willebrand factor
CSL Behring Lengnau AG1 citations68
US11155601B2Oct 26, 2021
Modified von Willebrand factor having improved half-life
CSL Behring Lengnau AG0 citations60
US11564976B2Jan 31, 2023
Methods for preparing modified von Willebrand Factor
CSL Behring Lengnau AG0 citations58
US11141466B2Oct 12, 2021
Modulation of FVIII immunogenicity by truncated VWF
CSL Behring Lengnau AG0 citations57
US11814421B2Nov 14, 2023
Truncated von Willebrand Factor polypeptides for treating hemophilia
CSL Behring Lengnau AG0 citations50
US10772936B2Sep 15, 2020
Methods for preparing modified von Willebrand factor
CSL Behring Lengnau AG0 citations48
US11890327B2Feb 6, 2024
Truncated von Willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
CSL Behring Lengnau AG0 citations44
AVENTIS BEHRING GMBH
5 patentsUS6248526B1Jun 19, 2001
Labeled primer for use in and detection of target nucleic acids
AVENTIS BEHRING GMBH128 citations97
US6573081B2Jun 3, 2003
Method for growing circoviruses
AVENTIS BEHRING GMBH39 citations91
US6183999B1Feb 6, 2001
Procedure for the detection of high virus concentrations in blood plasma and/or blood serum by means of the polymerase chain reaction
AVENTIS BEHRING GMBH13 citations73
US6831167B2Dec 14, 2004
Mutants of the factor VII-activating protease and detection methods using specific antibodies
AVENTIS BEHRING GMBH9 citations71
US7153679B2Dec 26, 2006
Marburg I mutant of factor VII activating protease (FSAP) as risk factor for arterial thrombosis
AVENTIS BEHRING GMBH9 citations69
CSL BEHRING GMBH
5 patentsUS7939632B2May 10, 2011
Proteolytically cleavable fusion proteins with high molar specific activity
CSL BEHRING GMBH40 citations92
US9458223B2Oct 4, 2016
Von willebrand factor variants having improved factor VIII binding affinity
CSL BEHRING GMBH8 citations82
US7863009B2Jan 4, 2011
Mutants of the factor VII-activating protease and detection methods using specific antibodies
CSL BEHRING GMBH0 citations49
US7442514B2Oct 28, 2008
Mutants of the factor VII-activating protease and detection methods using specific antibodies
CSL BEHRING GMBH0 citations49
US7803569B2Sep 28, 2010
Marburg I mutant of factor VII activating protease (FSAP) as risk factor for arterial thrombosis and methods of detecting FSAP and FSAP mutations
CSL BEHRING GMBH0 citations47
WEIMER THOMAS
4 patentsUS8575104B2Nov 5, 2013
Factor VIII, von willebrand factor or complexes thereof with prolonged in vivo half-life
WEIMER THOMAS18 citations89
US8765915B2Jul 1, 2014
Modified coagulation factor VIIa with extended half-life
WEIMER THOMAS8 citations79
US9290561B2Mar 22, 2016
Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life
WEIMER THOMAS1 citations49
US8828939B2Sep 9, 2014
Modified vitamin K dependent polypeptides
WEIMER THOMAS0 citations39
SCHULTE STEFAN
4 patentsUS8283319B2Oct 9, 2012
Therapeutic application of Kazal-type serine protease inhibitors
SCHULTE STEFAN33 citations89
US8754194B2Jun 17, 2014
Modified coagulation factors with prolonged in vivo half-life
SCHULTE STEFAN12 citations83
US9347051B2May 24, 2016
Coagulation factor X polypeptides with modified activation properties
SCHULTE STEFAN6 citations70
US9249404B2Feb 2, 2016
Coagulation factor X polypeptides with modified activation properties
SCHULTE STEFAN0 citations49